Levodopa

Parkinson's Disease

Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which dep...

[Articles] Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial

Extended-release carbidopa-levodopa might be a useful treatment for patients with Parkinson's disease who have motor fluctuations, with potential benefits including decreased off-time and reduced levo...

The AAPS Journal: Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients

Type: Original PaperMotor complications of Parkinson’s disease (PD) are a consequence of pulsatile dopaminergic stimulation from standard oral levodopa therapy. Levodopa–carbidopa intestinal gel (...

Human medicines European Public Assessment Report (EPAR): Levodopa/Carbidopa/Entacapone Orion, levodopa / carbidopa / entacapone, Revision: 2, Authorised

Human medicines European Public Assessment Report (EPAR): Levodopa/Carbidopa/Entacapone Orion, levodopa / carbidopa / entacapone, Revision: 1, Authorised

Depomed's DM-1992 meets Phase II Parkinson's endpoint

Depomed Inc. (NASDAQ:DEPO) said twice-daily DM-1992 met the primary endpoint vs. generic immediate-release (IR) carbidopa-levodopa dosed as needed (average of 4.8 doses/day) in a Phase II trial to tre...

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson's disease (PD) regimen, significantly improved the duration of the drugs' effectiveness in people with advanced PD, according...

Phase III success with extended-release carbidopa–levodopa formulation

An extended-release formulation of carbidopa–levodopa reduces the amount of off-time in patients with Parkinson’s disease, show results from a phase III randomized trial.

[Comment] Extended-release carbidopa-levodopa in Parkinson's disease

Levodopa with carbidopa is undoubtedly the gold standard of treatment for Parkinson's disease. But an initial spectacular benefit with this drug, known as the honeymoon period, is often compromised wi...

Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Patients.

Motor complications of Parkinson's disease (PD) are a consequence of pulsatile dopaminergic stimulation from standard oral levodopa therapy. Levodopa-carbidopa intestinal gel (LCIG) is infused continu...

Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.

Objective: Controlled-release levodopa/carbidopa (CR-LC) is often used to provide prolonged control of night-time motor symptoms in patients with Parkinson's disease (PD). Levodopa/carbidopa/entacapon...

Carbidopa/levodopa pharmacy errors in Parkinson's disease.

Outpatient pharmacy errors are common, but little is known about their occurrence in Parkinson's disease (PD). We prospectively studied carbidopa/levodopa pharmacy errors in a cohort of PD outpatients...

Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.

Background and purpose:  Catechol-O-methyltransferase inhibitors may be used to decrease levodopa requirement. The objective was to investigate whether the levodopa/carbidopa intestinal gel infusion...

Utilization of anti-Parkinson drugs in Australia: 1995-2009.

PURPOSE: To examine trends in the prescribing of anti-Parkinsonian drugs (APD) in Australia from 1995 to 2009. METHODS: We analyzed the Medicare Australia and Drug Utilisation Sub-Committee (DUSC) dat...